Navigation Links
Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
Date:5/26/2011

nvolve a number of risks and uncertainties.  The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which “Risk Factors” discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these for
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
2. Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
3. Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
4. Biovista Announces a Drug Repositioning Collaboration With Pfizer
5. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
6. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
7. Pfizer Wins CIO 100 Award for Patient Enrollment Optimization Solution From DecisionView
8. Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone)
9. Pfizer Animal Health Expands Global Commitment to a Safe Food Supply with a New Focus on Healthy Fish
10. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
11. Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... Outstanding Issues (LOI) from the European Medicines Agency,s Committee ... NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained release ... being evaluated for weight loss. The key ... adequately addressed by the Company based in part on ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... 2014 Immunology Summit-2014 ... Principle Investigators, scientists in the field, which includes ... at Case Western Reserve University School of Medicine, ... on “The effects of recombinant human IL-6 ... metalloproteinase-9”. Arya Biragyn, a Senior investigator at National ...
(Date:7/29/2014)... The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4
... FRANCISCO , Jan. 13 Today, endpoint ( ... users to design and deploy clinical trial IRT systems in ... Leveraging a background of more than 12 years designing Integrated ... designed PULSE to balance speed of deployment with flawless quality. ...
... ROCHESTER, N.Y. , Jan. 12 After a decade of ... decelerated and may have even fallen when adjusted for inflation.  That is ... the American Medical Association .   , "The era of rapid expansion ... Ray Dorsey , M.D. , a neurologist at the ...
... , ... Institute announces twenty-four exhibitors to showcase new products at the 17th Molecular Medicine Tri-Conference, ... Molecular Medicine Tri-Conference is the predominant event on the west coast focused on integrating ... ...
Cached Biology Technology:endpoint Introduces First Fully Configurable IRT System 2Study: Era of Rapid Growth in Biomedical Research Over 2Study: Era of Rapid Growth in Biomedical Research Over 3Study: Era of Rapid Growth in Biomedical Research Over 4Study: Era of Rapid Growth in Biomedical Research Over 5Study: Era of Rapid Growth in Biomedical Research Over 6A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 2A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 3A Host of New Products to be Showcased at 2010 Molecular Medicine Tri-Conference 4
(Date:7/30/2014)... Monash University Professor Steven Chown has been awarded ... Medal for Excellence in Antarctic Research. , SCAR, ... coordinates high quality international scientific research in the ... Antarctic region in the Earth system. The organisation ... Antarctic Treaty System, responsible for governing the region. ...
(Date:7/30/2014)... for spinal cord injury (SCI), traumatic brain injury (TBI) ... deal has been learned over the past 30 years ... that regulate axon growth, but this large body of ... Prof. Lemmon and his team from University of Miami ... causes, but a consensus is emerging that one contributing ...
(Date:7/30/2014)... , July 30, 2014 The Nano-Bio ... United States Air Force Research Laboratory (AFRL), has ... Binghamton University to develop electronics ... (HPM). The $425,000 project, with contributions from the ... i3 Electronics, Inc. ( Endicott, N.Y. ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... $50 million to a multi-institution collaborative headquartered at the ... cyberinfrastructure for the biological sciences. The renewal ... the Texas Advanced Computing Center (TACC) at the University ... New York, and University of North Carolina Wilmington (UNCW), ...
... Researchers have discovered why multiple myeloma, a difficult to cure ... effective treatment that can keep the disease at bay for ... colleagues at Princess Margaret Hospital in Toronto, researchers from Mayo ... in Phoenix were part of the team that conducted the ...
... NEW YORK , Sept. 18, 2013 ... research report is available in its catalogue: ... Global Biometrics Market ... the Market Grow Manifold,This study analyzes the ...
Cached Biology News:$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 2$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 3$50 million NSF grant to advance cyberinfrastructure for big data in life sciences 4Research team uncovers root cause of multiple myeloma relapse 2Emerging Opportunities in Global Biometrics Market 2Emerging Opportunities in Global Biometrics Market 3Emerging Opportunities in Global Biometrics Market 4Emerging Opportunities in Global Biometrics Market 5
Request Info...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... siRNA service provides the premium quality siRNAs ... Custom siRNAs can be readily ordered online ... sequence, or by providing the sense and ... Silencer Validated and Silencer Pre-designed siRNAs, which ...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
Biology Products: